Agency efforts to standardise benefit:risk assessment progress
This article was originally published in Scrip
The European Medicines Agency has released results from the first of a five-part project that aims to standardise for the first time the way in which it assesses the benefits and risks of medicines.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.